BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martí E, Segado A, Pastor-galán I, Amat P, Remigia MJ, Solano C, Navarro B. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Future Cardiology 2018;14:3-8. [DOI: 10.2217/fca-2018-0020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol 2020;86:533-47. [PMID: 31631392 DOI: 10.1111/bcp.14127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
2 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]